Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) released a Harris Poll showing 92% of Americans ages 45+ support blood-based colorectal cancer screening being covered with no co-pay similar to Medicare.
The survey reports Shield, an FDA-approved blood test, had 93% adherence in the first 100,000 tests and is covered by Medicare, VA Community Care, and TRICARE.
Guardant Health (Nasdaq: GH) announced that its Shield blood-based colorectal cancer screening test is now orderable through Quest Diagnostics' national test ordering and collection network.
Shield is the first blood test with full FDA approval as a primary CRC screening for average-risk adults 45+, available via Quest to nearly 650,000 clinician accounts, ~2,000 patient centers and ~6,000 in-office phlebotomists. Shield reported a 93% screening completion rate in the first 100,000 tests and is covered by Medicare, VA Community Care Network and TRICARE, with inclusion in updated NCCN CRC screening guidelines.
Guardant Health (Nasdaq: GH) launched Shield Across America on March 4, 2026, a coast-to-coast mobile screening tour delivering Shield, the first FDA-approved blood test for primary colorectal cancer screening, to over 100 communities with emphasis on rural areas.
The tour aims to raise screening rates—Shield recorded 93% adherence in its first 100,000 orders—and coincides with National Colorectal Cancer Awareness Month; Shield is covered by Medicare, VA Community Care, and TRICARE and is available by prescription.
Guardant Health (Nasdaq: GH) announced a partnership with actor Patrick Dempsey to raise awareness of colorectal cancer (CRC) screening and the FDA-approved Shield blood test during CRC Awareness Month (March 2026).
Key points: Shield is FDA-approved (2024) as a primary CRC screening option for adults 45+ at average risk, delivered via a routine blood draw, with results typically available within two weeks and real-world completion of 93% in the first 100,000 tests ordered. Shield was recently included in updated NCCN CRC screening guidelines.
Guardant Health (Nasdaq: GH) announced inducement equity grants approved February 23, 2026 under its 2023 Employment Inducement Incentive Award Plan.
The company granted 41,852 RSUs to 88 new non‑executive employees and one non‑qualified stock option for 4,965 shares (exercise price $94.42, closing price on February 23, 2026). RSUs vest one‑third annually; options vest one‑third after one year then monthly over 24 months.
Guardant Health (Nasdaq: GH) reported Q4 2025 revenue of $281.3M, up 39% YoY, and full-year 2025 revenue of $982.0M, up 33% YoY. Non-GAAP gross margin improved to 66%. Shield screening reached ~87,000 tests in 2025.
Management issued 2026 guidance: revenue of $1.25–1.28B (up 27–30%), oncology volume ~30% growth, screening revenue of $162–174M, and reduced free cash flow burn target of $185–195M.
Guardant Health (Nasdaq: GH) launched a Community Colorectal Cancer Screening Grant Program ahead of CRC Awareness Month in March. Selected organizations may receive up to 100 Shield blood tests per group, provided at no cost, to support community screening events and educational outreach.
Applications are due Feb. 17, 2026 (midnight PST) with approvals notified by Feb. 20, 2026. Guardant emphasizes access for underserved and underscreened communities and invites patient advocacy, non-profit, and public health groups to apply.
Guardant Health (Nasdaq: GH) announced participation in multiple investor conferences in February and March 2026. The company will host 1x1 meetings at BTIG on Feb 10, and deliver fireside chats at TD Cowen (Mar 4, 9:50 AM ET), Leerink (Mar 10, 1:00 PM ET) and Barclays (Mar 11, 1:00 PM ET).
Live and archived webcasts will be available in the Investors section at www.guardanthealth.com.
Guardant Health (Nasdaq: GH) announced publication in the Journal of Clinical Oncology of the largest study to date evaluating ctDNA for molecular residual disease (MRD) in resected stage III colon cancer.
In a phase III cohort of >2,000 patients, Guardant Reveal detected ctDNA in ~20% post-surgery and identified a four‑to‑six‑fold higher risk of recurrence or reduced survival versus standard staging; tumor fraction further stratified highest‑risk patients.
Guardant Health (Nasdaq: GH) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 19, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and archived replay will be available on the company’s Investors website.